Диссертация (1139777), страница 21
Текст из файла (страница 21)
et al. Preoperative staging of pelviclymph nodes in prostate cancer by 11C-choline PET. // J Nucl Med, 2003; 44:331–335.156.Kotzerke J., Prang J., Neumaier B. et al. Experience with carbon-11choline positron emission tomography in prostate carcinoma. // Eur J Nucl Med,2000; 27: 1415–1419.157.Schiavina R., Scattoni V., Castellucci P. et al. 11C-choline positronemission tomography/computerized tomography for preoperative lymph-nodestaging in intermediate-risk and high-risk prostate cancer: comparison withclinical staging nomograms.
// Eur Urol, 2008; 54: 392–401.158.Poulsen M.H., Bouchelouche K., Gerke O. et al. [18F]-fluorocholinepositron-emission/computed tomography for lymph node staging of patients withprostate cancer: preliminary results of a prospective study. // BJU Int, 2010; 106:639–643.159.Долгушин М.Б. ПЭТ/КТ с 18-фторхолином в режиме двухэтапногосканирования при биохимических рецидивах рака предстательной железы/М.Б.
Долгушин, А.А. Оджарова, А.И. Михайлов [и др.] // Онкоурология. –2015. – №2. – С. 46–54.160.Treglia G., Ceriani L., Sadeghi R. et al. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT inrestaging prostate cancer patients: a meta-analysis. // Clin Chem Lab Med, 2014;52(5): 725–33.161.Scattoni V., Picchio M., Suardi N. et al.
Detection of lymph-nodemetastases with integrated [11C]choline PET/CT in patients with PSA failureafter radical retropubic prostatectomy: results confirmed by open pelvicretroperitoneal lymphadenectomy. // Eur Urol, 2007; 52: 423–429.162.Husarik D.B., Mirabell R., Dubs M. et al. Evaluation of (18F)-cholinePET/CT for staging and restaging of prostate cancer. // Eur J Nucl Med Mol128Imaging, 2008; 35: 253–263.163.Schilling D., Schlemmer H.P., Wagner P.H. et al. Histological verificationof 11C-choline-positron emission/computed tomography-positive lymph nodes inpatients with biochemical failure after treatment for localized prostate cancer. //BJU Int, 2008; 102: 446–451.164.Rinnab L., Buchegger F., Simon J.
et al. [11C]Choline PET/CT for targetedsalvage lymph node dissection in patients with biochemical recurrence afterprimary curative therapy for prostate cancer. // Urol Int, 2008; 81: 191–197.165.Krause B.J., Souvatzoglou M., Tuncel M. et al. The detection rate of[(11)C]Choline-PET/CT depends on the serum PSA-value in patients withbiochemical recurrence of prostate cancer.
// Eur J Nucl Med Mol Imaging, 2008;35: 18–23.166.Giovacchini G., Picchio M., Parra R.G. et al. Prostate-specific antigenvelocity versus prostate specific antigen doubling time for prediction of 11Ccholine PET/CT in prostate cancer patients with biochemical failure after radicalprostatectomy. // Clin Nucl Med, 2012; 37: 325–331.167.РыболовМ.А.Рольпростатоспецифическогоантигенаиегокинетических характеристик при отборе больных для контрольной 11СХолинпозитронно-эмиссионной/компьютернойтомографиипослерадиотерапии или радикальной простатэктомии/ М.А. Рыболов, И.Я.
ДеЙонг, А.Й. Бреусма [и др.] // Нефрология. – 2011. – №4. – С. 55–61.168.Giovacchini G., Picchio M., Scattoni V. et al. PSA doubling time forprediction of 11C Choline PET/CT findings in prostate cancer patients withbiochemical failure after radical prostatectomy. // Eur J Nucl Med Mol Imaging,2010; 37: 1106–1116.169.Castellucci P., Fuccio C., Rubello D. et al. Is there a role for 11C-CholinePET/CT in the early detection of metastatic disease in surgically treated prostatecancer patients with a mild PSA increase <1.5 ng/ml? // Eur J Nucl Med MolImaging, 2011; 38: 55–63.170.Breeuwsma A.J., Rybalov M., Leliveld A.M. et al. Correlation of [11C]129Сholine PET-CT with time to treatment and disease-specific survival in men withrecurrent prostate cancer after radical prostatectomy.
// Q J Nucl Med MolImaging, 2012; 56: 440–446.171.Rybalov M., Breeuwsma A.J., Leliveld A.M. et al. Impact of total PSA, PSAdoubling time and PSA velocity on detection rates of 11C-Choline positronemission tomography in recurrent prostate cancer. // World J Urol, 2013; 31(2):319–323.172.Schillaci O., Calabria F., Tavolozza M. et al. Influence of PSA, PSAvelocity and PSA doublingtime on contrast-enhanced 18F-choline PET/CTdetection rate in patients with rising PSA after radical prostatectomy.
// Eur J NuclMed Mol Imaging, 2012; 39: 589–596.173.Graute V., Jansen N., Ubleis C. et al. Relationship between PSA kineticsand [18F]fluoro-choline PET/CT detection rates of recurrence in patients withprostate cancer after total prostatectomy. // Eur J Nucl Med Mol Imaging, 2012;39: 271–282.174.Carroll P. Rising PSA after a radical treatment. // Eur Urol, 2001; 40,Suppl. 2: 9–16.175.Dong J.T., Rinker-Schaeffer C.W., Ichikawa T. et al.
Prostate cancer –biology of metastasis and its clinical implications. // World J Urol, 1996; 14: 182–189.176.McMurtry C.T., McMurtry J.M., Metastatic prostate cancer: complicationsand treatment. // J Am Geriatr Soc, 2003; 51: 1136–1142.177.Yu K.K., Hawkins R.A. The prostate: diagnostic evaluation of metastaticdisease. // Radiol Clin North Am, 2000; 38: 139–157.178.Carlin B.I., Andriole G.L.
The natural history, skeletal complications, andmanagement of bone metastases in patients with prostate carcinoma. // Cancer,2000; 88: 2989–2994.179.Whitmore W.F. Natural history and staging of prostate cancer. // Urol ClinNorth Am, 1984; 11: 205–220.180.Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of130progression after PSA elevation following radical prostatectomy. // JAMA, 1999;281: 1591–1597.181.Beheshti M., Vali R., Waldenberger P.
et al. The use of F-18 choline PET inthe assessment of bone metastases in prostate cancer: correlation withmorphological changes on CT. // Mol Imaging Biol, 2009; 11: 446–454.182.Fuccio C., Castellucci P., Schiavina R. et al. Role of 11C-choline PET/CTin the restaging of prostate cancer patients showing a single lesion on bonescintigraphy.
// Ann Nucl Med, 2010; 24: 485–492.183.McCarthy M., Siew T., Campbell A. et al. (18)F-Fluoromethylcholine(FCH) PET imaging in patients with castration-resistant prostate cancer:prospective comparison with standard imaging. // Eur J Nucl Med Mol Imaging,2011; 38: 14–22.184.Fuccio C., Castellucci P., Schiavina R. et al. Role of 11C-choline PET/CTin the re-staging of prostate cancer patients with biochemical relapse and negativeresults at bone scintigraphy. // Eur J Radiol, 2012; 81: 893–896.185.Picchio M., Spinapolice E.G., Fallanca F.
et al. [11C]Choline PET/CTdetection of bone metastases in patients with PSA progression after primarytreatment for prostate cancer: comparison with bone scintigraphy. // Eur J NuclMed Mol Imaging, 2012; 39: 13–26.186.Garcia J.R., Moreno C., Valls E. et al.
Diagnostic performance of bonescintigraphy and (11)C-Choline PET/CT in the detection of bone metastases inpatients with biochemical recurrence of prostate cancer. // Rev Esp Med NuclImagen Mol, 2015; 34(3): 155–61.187.Beheshti M, Vali R, Waldenberger et al. The use of F-18 choline PET in theassessment of bone metastases in prostate cancer: correlation with morphologicalchanges on CT. // Mol Imaging Biol, 2010; 12: 360.188.Amanie J., Jans H.S., Wuest M.
et al. Analysis of intraprostatic therapeuticeffects in prostate cancer patients using [11C]-choline PET/CT after external-beamradiation therapy. // Curr Oncol, 2013; 20: 104–110.189.Challapalli A., Barwick T.,Tomasi G. et al. The potential of [11C]choline131PET/CT as a novel imaging biomarker for predicting early treatment response inprostate cancer. // Nucl Med Commun, 2014; 35: 20–29.190.Casamassima F., Masi L., Menichelli C. et al. Efficacy of eradicativeradiotherapy for limited nodal metastases detected with choline PET scan inprostate cancer patients. // Tumori, 2011; 97: 49–55.191.Beheshti M., Haim S., Zakavi R.
et al. Impact of 18 F-choline PET/CT inprostate cancer patients with biochemical recurrence: influence of androgendeprivation therapy and correlation with PSA kinetics. // J Nucl Med, 2013; 54:833–840.192.Detti B1., Scoccianti S., Franceschini D.et al. Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radicaltreatment. // J Cancer Res Clin Oncol, 2013; 139(3): 521–528.193.Cesi F., Castellucci P., Graziani T. et al. 11C-Choline PET/CT detects thesite of relapse in the majority of prostate cancer patients showing biochemicalrecurrence after EBRT. // Eur J Nucl Med Mol Imaging, 2014; 41(5): 878–886.194.Marzola M.C1., Chondrogiannis S., Ferretti A.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
